The European Medicines Agency said on Tuesday it had launched a “rolling review” of France’s Sonofi coronavirus, which could be approved for use in the European Union.
“The EMA will review compliance with the usual EU standards for videoprotein for effectiveness, safety and quality,” the agency said.
Sanofi Medicine, developed with the British firm GSK, adds four others to the EMA’s review list, including Russia’s Sputnik V and China’s Sinovic.
Unlike mRNA vaccines, which need to be stored at extremely cold temperatures, the snooze job can be kept close to room temperature, possibly aiding in the rollout.
The jaw will need two doses like other vaccines on the market.
It contains an antigen made from sonophyte, which accelerates the production of antibacterial antibodies, including GSK-related technology, a substance that is produced by a vaccine. Strengthens the immune system.
Sonofi and GSK said in May that they would begin final testing of their drug in Phase 2 clinical trials after achieving a “strong rate of neutralizing antibody response”.
The EMA said the decision to launch the study was based on preliminary findings that “suggest that the vaccine stimulates the production of antibodies that target SARS COVID 2, the virus that causes COVID-19.” Yes, and can help prevent this disease. “
“The EMA will examine the data when it becomes available to determine if the benefits outweigh the risks,” the agency said, adding that it could not provide a timeline for review. Is.
There are four vaccines in the European Union with EMA approval, Pfizer Biotech, Moderna, AstraZeneca and Johnson & Johnson.
Copyright AFP. All rights reserved.